Merck & Company Inc (MRK)vsNeuphoria Therapeutics Inc (NEUP)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
NEUP
Neuphoria Therapeutics Inc
$3.73
0.00%
HEALTHCARE · Cap: $20.38M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates -501763867% more annual revenue ($66.57B vs $-13,267). MRK leads profitability with a 4.8% profit margin vs 0.0%. NEUP earns a higher WallStSmart Score of 47/100 (D+).
MRK
Hold36
out of 100
Grade: F
NEUP
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for NEUP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 110513.0%
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Operating Margin, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NEUP scores higher overall (47/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is a groundbreaking biotechnology firm focused on revolutionizing mental health disorders treatment via psychedelic compounds and advanced drug delivery systems. The company boasts a promising pipeline of preclinical candidates, strategically targeting significant unmet needs within the mental healthcare sector, coinciding with the increasing acceptance of alternative therapies. As a frontrunner in the rapidly evolving psychedelic therapy market, Neuphoria offers a compelling investment proposition for institutional investors keen on supporting innovative solutions that may fundamentally alter the landscape of mental health treatment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?